2026-08-28
The Qianhai 15% corporate income tax (CIT) preference has been extended through 31 December 2027 by Cai Shui No. 3, keeping Qianhai's effective rate on par with Hong...
2026-08-28
In May 2026 the General Administration of Customs issued a 20-measure package specifically designed to accelerate the flow of goods, people and data across the Guangdong–Hong Kong–Macao Greater Bay...
2026-08-28
The 2026 action plan supports rules for drug segmented manufacturing to facilitate overseas marketing-authorisation holders in cross-border segmented production. 2026年行动方案支持出台药品分段生产细则，便利境外药品上市许可持有人开展跨境分段生产。Pilot regions for biotechnology and wholly-foreign-owned hospitals will be...
2026-08-28
Market access hinges on NMPA registration, not foreign approval — an FDA/EMA licence does not register a product in China. 市场准入关键在于NMPA注册而非境外批准——FDA或EMA许可并不等于在中国注册。Imported drugs and devices need a registered China...
2026-08-28
At the 17 August 2026 press conference marking China's Doctors' Day, Guangdong's health commission reported that visits by foreign patients at the 25 pilot international-medical-service hospitals grew 95.6% year...
2026-08-28
On 15 May 2026 the revised Implementation Regulations of the Drug Administration Law took effect, with Article 32 expressly allowing segmented (split-site) production of qualifying innovative drugs under a...
2026-08-28
The "Pilot Work Plan for Expanding Opening in the Wholly Foreign-Owned Hospital Sector" (NHC, MOFCOM et al., Guowei Yizhengfa No. 36) permits wholly foreign-owned hospitals in nine provincial...
2026-08-28
Wholly-foreign-owned hospitals are piloted in nine regions — Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and Hainan island — under the Nov-2024 pilot plan; outside those areas foreign-invested...
2026-08-28
Imported medical devices still require NMPA registration by risk class (I/II/III), and Class II/III overseas manufacturers must register their production sites with the NMPA before any China market entry....
2026-08-28
China's innovative-drug market is projected to exceed ¥1.3 trillion in 2026, with 2025 out-licensing deals reaching roughly US$135 billion and the first quarter of 2026 alone surpassing US$60 billion....